Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

Table 2 Systemic inflammation parameters and their prognostic impact on overall survival

Parameter	n (%)	Median OS, months	HR (95% CI)	p-value^a
NLR
< 3	35 (49.3%)	7.8	1.934 (1.1–3.3)	0.014
≥ 3	36 (50.7%)	13.7	1.934 (1.1–3.3)	0.014
PLR
< 200	40 (56.3%)	5.4	1.567 (0.9–2.7)	0.096
≥ 200	31 (43.7%)	13.0	1.567 (0.9–2.7)	0.096
Serum albumin levels
< 3.6 g/dL	14 (19.4%)	4.9	2.142 (1.1–4.5)	0.040
≥ 3.6 g/dL	47 (65.3%)	12.4	2.142 (1.1–4.5)	0.040
Unknown	11 (15.3%)	–	–	–
SIS
0	25 (35.2%)	16.0	–	0.004
1	18 (25.4%)	7.8
2	21 (29.6%)	5.7
3	7 (9.9)	4.0
SIS groups
0	25 (35.2%)	16.0	0.475 (0.3–0.8)	0.008
1–3	46 (64.8%)	7.3	0.475 (0.3–0.8)	0.008

CI Confidence interval, HR Hazard ratio, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, SIS Systemic inflammation score
^aSignificant values are indicated in bold

ISSN: 1471-2407